Sector Specific - Pharmaceutical
The robust growth in sales and profit are expected to come from Aurobindo Pharma, Biocon, Cadila Healthcare, Glenmark Pharma, Lupin, Orchid Chemicals, Plethico Pharma and Ranbaxy Laboratories. Sales growth is muted for Dishman Pharma, Divi’s Labs, Dr Reddy’s Labs and Sun Pharmaceuticals. GSK Pharma is expected to improve its performance with double-digit growth in net sales, while Dr Reddy’s Labs, Orchid Pharma and Ranbaxy Labs are likely to turn around.
Aurobindo Pharmaceuticals shares gained the most in the past eight months, up 732 per cent over its 52-week low on March 9. Expansion of manufacturing capacities, vertical integration and the building of a strong product pipeline, the supply arrangement deal with Pfizer and the potential of similar deals with other multi-national corporations are expected to ensure a ramp-up in revenues and earnings in the coming years.
Ranbaxy Laboratories has moved up by more than 200 per cent over its 52-week low, as analysts expect the company to come into the black in 2009-10 from a net loss last year. The launch of the generic drug, Valtrex, in the US is expected to fetch about Rs 850 crore at the current rate of exchange and a net margin of 60 per cent leading to a profit of $111 million (Rs 515 crore) during the exclusivity period.
Dr Reddy’s Labs have gained over 200 per cent since March on robust growth prospects. Analysts expect the company to post a turnaround in 200910, with a net profit of Rs 820 crore as against anet loss of Rs 917 crore in 2008-09. Going forward, the company’s alliance with GSK Pharmaceuticals is expected to be a revenue driver in a few years.
Cipla surged to its all-time high level in November, up 86 per cent since its 52-week low on January 22. The company expects to perform well in 200910, with net sales growth of around 18 per cent, while net profit is expected to be up by 37 per cent. Recently, the company had entered into a joint venture with a Chinese company for bio-similars and it is planning to bring out the JV’s first product by 2010.
It is aiming at entering the market with a new biotech product, off-patent and with a market size of $5 billion. Japan and Europe have already given their regulatory approvals and this is also likely to happen in the next couple of quarters in the US.
Orchid Chemicals has risen 225 per cent since March 12, but low on robust growth prospects. The company suffered a setback in 2008-09 due to higher interest cost on borrowing and is expected to turn around in 200910, posting a net profit of Rs 70 crore. According to the pharma analyst at Angel Broking, the company is likely to be benefited by the US FDA approval to launch Tazo+Pip in the US, in collaboration with Apotex. The company would augment revenues by $84 million during the exclusivity period. The net margin is expected to be in the range of 25 per cent and likely to add $21 million in net profit.
(updated - 04 Dec 2009)
On Growth Track - Pharma Companies
The Bombay Stock Exchange’s pharmaceutical has outperformed its benchmark, the BSE Sensex, surging 33 per cent in six months (Sensex up 17 per cent) and 21 per cent in the past three months (Sensex up 8 per cent), indicating that investors have started re-rating pharmaceutical companies.
The change in outlook saw the BSE Healthcare Index, as well as front-line and mid-cap pharma stocks such as Cipla, Dr Reddy’s Labs, Lupin, Ranbaxy Labs, Piramal Healthcare, IPCA Labs and Cadila Healthcare hitting two-year highs last week.
The performance was led by positive news flow across the sector. The pharma companies suffered a setback in 2008-09, largely due to mark to market (revaluing assets at their current price) losses on derivative products and Foreign Currency Convertible Bonds, due to depreciation of the rupee against the dollar.
Stock Market Indian
Welcome to the Indian Stock Market
Your Way To Earn
Disclaimer: Information presented on this site is a guide only. It may not necessarily be correct and is not intended to be taken as financial advice nor has it been prepared with regard to the individual investment needs and objectives or financial situation of any particular person. Stock quotes are believed to be accurate and correctly dated, but www.stockmarketindian.com does not warrant or guarantee their accuracy or date.
www.stockmarketindian.com takes no responsibility for any investment decisions based on recommendations provided on website.
Financial contents like Technical charts, historical charts and quotes are taken from NSE and Yahoo sites.
Note - All quotes are delayed by 15 minutes and unless specified.
Please read at www.stockmarketindian.com/disclaimer.php before using any material or advice given at www.stockmarketindian.com
Copyright © 2009 Stockmarketindian.com. All Rights Reserved.
